Drug Target Review2025-12-08T09:00:32
What if a T-cell therapy could activate only inside a tumour? New preclinical data on Molecular Partners’ Switch-DARPin suggest it may do just that.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2023-11-20T13:43:43
Sponsored by Merck
2023-03-02T13:57:58
Sponsored by Cell Signaling Technology
2023-01-19T15:38:17
Sponsored by Cell Signaling Technology
2026-09-24T06:30:00
Contributor Dr Dan Benjamin, Drug Target Review
Site powered by Webvision Cloud